Sosei Heptares Turns To AI In GPCR-Focused Drug Discovery Pact
Duo Is Using AI To Identify GPCR Targets Across Multiple Disease Areas
Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.
You may also be interested in...
Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.
Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.